---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-002184"
form_type: "8-K"
ticker: "QTRX"
cik: "0001503274"
company_name: "Quanterix Corp"
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:33:46.247591+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Quanterix Q4 revenue up 22% to $31.5M, net loss narrows; guides FY2024 revenue $139-144M

## Summary
- Q4 revenue $31.5M (+22% YoY); GAAP gross margin 53.2% (up from 48.8%); net loss $12.4M vs $18.6M.
- Full-year 2023 revenue $122.4M (+16%); GAAP gross margin 57.7% vs 44.4%; net loss $32.3M vs $96.7M.
- Completed corporate transformation; new assays in production. Collaborations with Mayo Clinic, Mass General Brigham, others for Alzheimer's diagnosis.
- 2024 guidance: revenue $139-144M (research-only), GAAP gross margin 57-61%, non-GAAP 51-55%, cash usage $25-30M.
- Eli Lilly launched pTau217 blood-based diagnostic test on Quanterix platform.

## SEC filing metadata
- accession: 0001558370-24-002184
- form_type: 8-K
- ticker: QTRX
- cik: 0001503274
- company_name: Quanterix Corp
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503274/000155837024002184/0001558370-24-002184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503274/000155837024002184/tmb-20240229x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-002184
- JSON: https://secwatch.observer/filing/0001558370-24-002184.json
- Plain text: https://secwatch.observer/filing/0001558370-24-002184.txt

## Key facts
- Earnings Releases
  Quanterix Corp reported the fourth quarter and twelve months ended December 31, 2023 results: revenue $31.5 million, net income Net loss was $12.4 million. Guidance initiated.
  - Period: the fourth quarter and twelve months ended December 31, 2023
  - Revenue: $31.5 million
  - Net income: Net loss was $12.4 million
  - Guidance: initiated
  - Result: reported results
  source text: biomarker testing to support the rollout of new Alzheimer’s therapies and to aid providers in the diagnosis of the disease.” Fourth Quarter Financial Highlights ● Revenue was $31.5 million, a 22% increase from $25.8 million for the corresponding prior year period. ● GAAP gross margin was 53.2% as compared to 48.8% for the corresponding prior year period. Non-GAAP
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503274/000155837024002184/0001558370-24-002184-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.